Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effect of corticosteroids on the frequency and severity of Mylotarg® infusion-related adverse events, to evaluate the effect of corticosteroids on the efficacy of Mylotarg® induced complete response (CR) and complete response with incomplete platelet recovery (CRp) at one-month post treatment.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00304447
Study type Interventional
Source Wyeth is now a wholly owned subsidiary of Pfizer
Contact
Status Completed
Phase Phase 4
Start date April 2002
Completion date January 2004

See also
  Status Clinical Trial Phase
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT01716793 - Risk-adapted Therapy for Adult Acute Myeloid Leukemia. Phase 2
Terminated NCT00152594 - Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia Phase 3
Completed NCT01723657 - Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT01034592 - Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia N/A
Completed NCT00406393 - Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) Phase 3
Recruiting NCT00126321 - Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML) Phase 2
Recruiting NCT00449319 - AML Treatment in Untreated Adult Patients N/A
Completed NCT00186381 - Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission Phase 2
Completed NCT00962767 - Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission Phase 3
Completed NCT01756118 - A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia Phase 1
Terminated NCT01339910 - Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Phase 3
Completed NCT00201240 - Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Phase 2
Terminated NCT01050946 - Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit Phase 2
Terminated NCT00446303 - A Phase II Study of Maintenance With Azacitidine in MDS Patients Phase 2
Completed NCT00044486 - Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) Phase 3
Active, not recruiting NCT02158858 - A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis Phase 1/Phase 2
Completed NCT00286845 - Use of the MiCK Assay for Apoptosis in AML Phase 1
Completed NCT00251368 - Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia Phase 1
Terminated NCT00048100 - Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes Phase 1